IOVANCE BIOTHERAPEUTICS, INC. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 32.73 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-06
- IOVANCE BIOTHERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 34.13M shares, a 2.31% increase year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-03-31 was 33.36M shares, a 1.94% decline year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2024-03-31 was 34.01M shares, a 29.03% increase year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2023-03-31 was 26.36M shares, a 30.36% increase year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 29.67M shares, a 4.12% decline from fiscal 2024.
- IOVANCE BIOTHERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 30.94M shares, a 20.92% increase from fiscal 2023.
- IOVANCE BIOTHERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 25.59M shares, a 22.57% increase from fiscal 2022.
- IOVANCE BIOTHERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 20.88M shares, a 25.35% increase from fiscal 2021.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month |
|---|---|---|---|---|
| 2026-06-30 | 32.73M shares 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | 34.13M shares 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | 29.67M shares 10-K · filed 2026-02-24 | |||
| 2025-09-30 | 31.10M shares 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | 33.01M shares 10-Q · filed 2026-08-06 | |||
| 2025-03-31 | 33.36M shares 10-Q · filed 2026-05-07 | |||
| 2024-12-31 | 30.94M shares 10-K · filed 2026-02-24 | |||
| 2024-09-30 | 31.96M shares 10-Q · filed 2025-11-06 | |||
| 2024-06-30 | 33.91M shares 10-Q · filed 2025-08-07 | |||
| 2024-03-31 | 34.01M shares 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | 25.59M shares 10-K · filed 2026-02-24 | |||
| 2023-09-30 | 26.23M shares 10-Q · filed 2024-11-07 | |||
| 2023-06-30 | 26.76M shares 10-Q · filed 2024-08-08 | |||
| 2023-03-31 | 26.36M shares 10-Q · filed 2024-05-09 | |||
| 2022-12-31 | 20.88M shares 10-K · filed 2025-02-27 | |||
| 2022-09-30 | 20.44M shares 10-Q · filed 2023-11-07 | |||
| 2022-06-30 | 20.15M shares 10-Q · filed 2023-08-08 | |||
| 2022-03-31 | 20.22M shares 10-Q · filed 2023-05-10 | |||
| 2021-12-31 | 16.66M shares 10-K · filed 2024-02-28 | |||
| 2021-09-30 | 16.67M shares 10-Q · filed 2022-11-03 | |||
| 2021-06-30 | 18.77M shares 10-Q · filed 2022-08-04 | |||
| 2021-03-31 | 18.41M shares 10-Q · filed 2022-05-05 | |||
| 2020-12-31 | 16.33M shares 10-K · filed 2023-02-28 | |||
| 2020-09-30 | 16.45M shares 10-Q · filed 2021-11-04 | |||
| 2020-06-30 | 16.27M shares 10-Q · filed 2021-08-05 | |||
| 2020-03-31 | 15.83M shares 10-Q · filed 2021-05-06 | |||
| 2019-12-31 | 13.20M shares 10-K · filed 2022-02-24 | |||
| 2019-09-30 | 13.21M shares 10-Q · filed 2020-11-05 | |||
| 2019-06-30 | 15.20M shares 10-Q · filed 2020-08-06 | |||
| 2019-03-31 | 15.28M shares 10-Q · filed 2020-05-05 | |||
| 2018-12-31 | 12.91M shares 10-K · filed 2021-02-25 | |||
| 2018-09-30 | 13.37M shares 10-Q · filed 2019-11-04 | |||
| 2018-06-30 | 17.80M shares 10-Q · filed 2019-08-01 | |||
| 2018-03-31 | 20.85M shares 10-Q · filed 2019-05-07 | |||
| 2017-12-31 | 20.71M shares 10-K · filed 2020-02-25 | |||
| 2017-09-30 | 22.04M shares 10-Q · filed 2018-11-06 | |||
| 2017-06-30 | 22.25M shares 10-Q · filed 2018-08-07 | |||
| 2017-03-31 | 22.60M shares 10-Q · filed 2018-05-10 | |||
| 2016-12-31 | 22.15M shares 10-K · filed 2019-02-28 | |||
| 2016-09-30 | 21.11M shares 10-Q · filed 2017-11-02 | |||
| 2016-06-30 | 24.09M shares 10-Q · filed 2017-08-03 | |||
| 2016-03-31 | 11.66M shares 10-Q · filed 2017-05-03 | |||
| 2015-12-31 | 11.06M shares 10-K · filed 2018-03-12 | |||
| 2015-09-30 | 12.28M shares 10-Q · filed 2016-11-04 | |||
| 2014-12-31 | 16.57M shares 10-K · filed 2017-03-09 | |||
| 2013-12-31 | 12.37M shares 10-K · filed 2015-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |